Why Guardant Health, Inc. (GH) Stock Rose 4.7% on Sep 15, 2026
The clearest new catalyst: Shield coverage by EviCore by Evernorth.
Why did GH stock rise?
Guardant Health rose 4.7% on September 15, 2026, driven by a major insurance coverage expansion for its Shield colorectal cancer screening blood test and positive momentum from a healthcare conference presentation. The day before, the company announced that EviCore by Evernorth—a major utilization management platform—would cover Shield for colorectal cancer screening, a significant step toward broader adoption. On the session itself, Guardant presented at the Morgan Stanley Global Healthcare Conference, reinforcing investor confidence in its precision oncology portfolio.
- Shield coverage by EviCore by Evernorth: Guardant Health announced on September 14 that its Shield blood test for colorectal cancer screening would be covered by EviCore by Evernorth, a major utilization management and prior authorization platform. This coverage decision removes a key barrier to adoption and expands access to the test across a large patient population.
- Morgan Stanley Healthcare Conference presentation: On September 15, Guardant Health presented at the Morgan Stanley 24th Annual Global Healthcare Conference, providing investors with direct insight into the company's precision oncology strategy and commercial execution, reinforcing positive sentiment around Shield and Guardant360 liquid biopsy volumes.
Initial detection
BestStocks first flagged GH intraday on Sep 15, 2026; this analysis was finalized after the close using the confirmed +4.7% session move and additional catalyst research.
Show the initial intraday note
Guardant Health shares rose 3.69% to $174.03 following bullish analyst momentum. UBS raised its price target from $175 to $225 with a Buy rating after strong Q2 results and raised full-year guidance, while Rothschild & Co initiated coverage with a Buy rating and $203 price target (web_catalyst). Expanding adoption of the Shield colorectal cancer screening test and Guardant360 liquid biopsy volumes continue to drive positive coverage. Volume of 719k shares (1.35x normal for this time of session) is consistent with typical intraday trading.
What to watch next: GH earnings on 2026-10-28 (date not yet confirmed; consensus estimate -$0.28 EPS) and the World Conference on Lung Cancer presentations for updates on Shield adoption metrics and liquid biopsy volume trends.
Frequently asked questions
Why did Guardant Health, Inc. (GH) stock rise on Sep 15, 2026?
Guardant Health rose 4.7% on September 15, 2026, driven by a major insurance coverage expansion for its Shield colorectal cancer screening blood test and positive momentum from a healthcare conference presentation. The day before, the company announced that EviCore by Evernorth—a major utilization management platform—would cover Shield for colorectal cancer screening, a significant step toward broader adoption. On the session itself, Guardant presented at the Morgan Stanley Global Healthcare Conference, reinforcing investor confidence in its precision oncology portfolio.
How much did GH stock rise on Sep 15, 2026?
GH rose 4.7% during the Sep 15, 2026 trading session.
What were the main drivers behind GH's move?
Shield coverage by EviCore by Evernorth; Morgan Stanley Healthcare Conference presentation.